Duchenne Muscular Dystrophy is a significant neurodegenerative disorder affecting millions worldwide. This page provides comprehensive information about the disease, including its mechanisms, symptoms, diagnosis, and treatment approaches.
Duchenne Muscular Dystrophy (DMD) is the most common and severe form of childhood muscular dystrophy, affecting approximately 1 in 3,500-5,000 live male births [1]. It is an X-linked recessive disorder caused by mutations in the DMD gene that result in the absence or severe reduction of functional dystrophin protein, leading to progressive muscle degeneration, loss of ambulation, and premature death [2].
¶ Genetics and Molecular Biology
The DMD gene is one of the largest known human genes, spanning over 2.2 megabases on chromosome Xp21.1. It encodes dystrophin, a critical cytoskeletal protein that provides structural stability to muscle cell membranes [3].
- Frameshift/nonsense mutations: ~60-70% of cases, cause premature stop codons
- Large deletions: ~60-70% of cases, typically involve one or more exons
- Duplications: ~10-15% of cases
- Small mutations: ~20-25% of cases (missense, splice site, small deletions)
Dystrophin (427 kDa) is a rod-shaped cytoplasmic protein that:
- Connects the actin cytoskeleton to the dystrophin-associated glycoprotein complex (DGC)
- Stabilizes muscle cell membranes during contraction
- Prevents membrane damage from mechanical stress
- Has multiple neuronal isoforms (Dp140, Dp71) important for cognitive function
The absence of functional dystrophin leads to:
- Membrane fragility: Mechanical stress causes sarcolemmal tears
- Calcium dysregulation: Influx through damaged membranes triggers proteolysis
- Oxidative stress: Mitochondrial dysfunction increases reactive oxygen species
- Inflammation: Immune cell infiltration accelerates muscle damage
- Fibrosis: Replacement of muscle with adipose and connective tissue
- Sarcolemmal dysfunction: Reduced neuronal nitric oxide synthase (nNOS) localization
- Mitochondrial abnormalities: Energy production deficits
- Autophagy impairment: Accumulation of damaged proteins and organelles
- Satellite cell exhaustion: Impaired muscle regeneration capacity
¶ Age of Onset and Progression
Infancy (0-2 years):
- Hypotonia, motor delay
- Delayed sitting, walking
- Calf pseudohypertrophy
- Gower's sign (using hands to climb up legs when rising)
Early Childhood (3-5 years):
- Progressive proximal weakness
- Waddling gait
- Difficulty climbing stairs
- Frequent falls
Late Childhood (6-12 years):
- Loss of running ability
- Progressive scoliosis
- Cardiomyopathy onset (usually by age 10)
- Respiratory function decline
Adolescence (13+ years):
- Loss of ambulation (typically by age 12-15)
- Severe scoliosis requiring surgical intervention
- Cardiomyopathy progression
- Respiratory insufficiency requiring support
- Dilated cardiomyopathy develops in nearly all patients
- Cardiac MRI shows early changes before symptoms
- Arrhythmias are common
- Requires aggressive monitoring and treatment
¶ Cognitive and Behavioral
- Learning disabilities in ~30% of patients
- Intellectual disability in ~20%
- Attention deficit hyperactivity disorder (ADHD)
- Autism spectrum disorders more prevalent
- Executive function deficits
- Physical examination: Characteristic pattern of weakness
- Gower's sign: Pathognomonic for proximal muscle weakness
- Calf pseudohypertrophy: Due to fatty infiltration
- Creatine kinase (CK): Extremely elevated (10-100x normal)
- Aldolase: Elevated
- Electromyography: Myopathic changes
- Multiplex ligation-dependent probe amplification (MLPA): Detects deletions/duplications
- Next-generation sequencing (NGS): Identifies small mutations
- Carrier testing: Important for family planning
- Historical gold standard
- Shows absence of dystrophin (immunohistochemistry)
- Replaced by genetic testing in most cases
Corticosteroids (Standard of Care):
- Prednisone/prednisolone: 0.75 mg/kg/day
- Deflazacort: 0.9 mg/kg/day
- Benefits: Slows disease progression, prolongs ambulation
- Side effects: Weight gain, osteoporosis, cataracts, adrenal suppression
Exon Skipping Therapies:
- Exondys 51 (eteplirsen): Targets exon 51 skipping (~13% of patients)
- Vyondys 53 (golodirsen): Targets exon 53 (~8% of patients)
- Viltepso (viltolarsen): Targets exon 53 (Japan)
- Amondys 45 (casimersen): Targets exon 45 (~8% of patients)
Gene Therapy:
- Elevidys (SRP-9001, micro-dystrophin): AAV-mediated delivery
- FDA-approved for patients ages 4-5 (2023)
- Shows functional improvement in clinical trials
- Requires careful patient selection and monitoring
Physical Therapy:
- Stretching routines to prevent contractures
- Gentle exercise to maintain function
- Assistive devices as needed
Cardiac Management:
- ACE inhibitors or ARBs: Cardiac protection
- Beta-blockers: For cardiomyopathy
- Pacemakers: For conduction abnormalities
- Regular echocardiograms and ECGs
Respiratory Care:
- Pulmonary function monitoring (FVC, FEV1)
- Non-invasive ventilation (BiPAP) when needed
- Cough assist devices
- Secretion clearance techniques
Orthopedic Management:
- Scoliosis monitoring and surgery
- Night-time orthoses to prevent contractures
- Physical therapy
Nutritional Support:
- Calorie-dense diets to maintain weight
- Calcium and vitamin D supplementation
- Monitoring for dysphagia
- Utrophin modulators: Upregulation of utrophin as dystrophin substitute
- Myostatin inhibitors: Blocking muscle growth inhibitors
- Stem cell therapy: Various approaches in development
- CRISPR-based gene editing: Preclinical and early clinical stages
- Mean life expectancy: Early 30s (historically late teens)
- Current improvements: Many patients now living into 40s-50s with modern care
- Leading causes of death: Respiratory failure, cardiomyopathy
- Quality of life: Significantly improved with multidisciplinary care
The study of Duchenne Muscular Dystrophy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Mendell JR et al., Duchenne muscular dystrophy (2023)
- Bushby K et al., Diagnosis and management of Duchenne muscular dystrophy (2024)
- Emery AEH et al., The history of Duchenne muscular dystrophy (2023)
- Birnkrant DJ et al., Current treatment of Duchenne muscular dystrophy (2024)
- Mercuri E et al., Diagnosis and management of Duchenne muscular dystrophy (2022)